Tags

Type your tag names separated by a space and hit enter

The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial.
Pancreas. 2008 Nov; 37(4):445-8.P

Abstract

OBJECTIVES

Patients undergoing therapeutic endoscopic retrograde cholangiopancreatography (ERCP) are at a higher risk of developing post-ERCP pancreatitis than patients undergoing diagnostic ERCP. The aim of this study was to evaluate the effectiveness of somatostatin in preventing post-therapeutic ERCP pancreatitis.

METHODS

This placebo-controlled, double-blind, randomized study involved 391 patients in 3 hospitals who required therapeutic ERCP. Patients were assigned to receive either somatostatin or placebo. The incidence of pancreatitis and hyperamylasemia after performing ERCP was compared between the somatostatin and placebo groups.

RESULTS

Pancreatitis occurred in statistically significantly fewer ERCP patients who received somatostatin (7/193: 3.6%) than placebo (19/198: 9.6%; P = 0.02). With regard to the individual ERCP procedures, statistically significant reductions in post-ERCP pancreatitis were seen in patients treated with somatostatin who had stoneremoval (P = 0.04) and endoscopic papillary balloon dilation (P= 0.03). The incidence of hyperamylasemia was lower in the somatostatin group (7.8%) than in the placebo group (12.6%), although this difference was not statistically significant (P > 0.05).

CONCLUSIONS

A significantly lower incidence of post-ERCP pancreatitis occurred in patients who received somatostatin prophylaxis. This finding suggests that the administration of somatostatin is useful in preventing pancreatitis in patients undergoing therapeutic ERCP.

Authors+Show Affiliations

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. happymap@skku.eduNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

18953260

Citation

Lee, Kyu Taek, et al. "The Prophylactic Effect of Somatostatin On Post-therapeutic Endoscopic Retrograde Cholangiopancreatography Pancreatitis: a Randomized, Multicenter Controlled Trial." Pancreas, vol. 37, no. 4, 2008, pp. 445-8.
Lee KT, Lee DH, Yoo BM. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial. Pancreas. 2008;37(4):445-8.
Lee, K. T., Lee, D. H., & Yoo, B. M. (2008). The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial. Pancreas, 37(4), 445-8. https://doi.org/10.1097/MPA.0b013e3181733721
Lee KT, Lee DH, Yoo BM. The Prophylactic Effect of Somatostatin On Post-therapeutic Endoscopic Retrograde Cholangiopancreatography Pancreatitis: a Randomized, Multicenter Controlled Trial. Pancreas. 2008;37(4):445-8. PubMed PMID: 18953260.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial. AU - Lee,Kyu Taek, AU - Lee,Don Haeng, AU - Yoo,Byung Moo, PY - 2008/10/28/pubmed PY - 2008/12/17/medline PY - 2008/10/28/entrez SP - 445 EP - 8 JF - Pancreas JO - Pancreas VL - 37 IS - 4 N2 - OBJECTIVES: Patients undergoing therapeutic endoscopic retrograde cholangiopancreatography (ERCP) are at a higher risk of developing post-ERCP pancreatitis than patients undergoing diagnostic ERCP. The aim of this study was to evaluate the effectiveness of somatostatin in preventing post-therapeutic ERCP pancreatitis. METHODS: This placebo-controlled, double-blind, randomized study involved 391 patients in 3 hospitals who required therapeutic ERCP. Patients were assigned to receive either somatostatin or placebo. The incidence of pancreatitis and hyperamylasemia after performing ERCP was compared between the somatostatin and placebo groups. RESULTS: Pancreatitis occurred in statistically significantly fewer ERCP patients who received somatostatin (7/193: 3.6%) than placebo (19/198: 9.6%; P = 0.02). With regard to the individual ERCP procedures, statistically significant reductions in post-ERCP pancreatitis were seen in patients treated with somatostatin who had stoneremoval (P = 0.04) and endoscopic papillary balloon dilation (P= 0.03). The incidence of hyperamylasemia was lower in the somatostatin group (7.8%) than in the placebo group (12.6%), although this difference was not statistically significant (P > 0.05). CONCLUSIONS: A significantly lower incidence of post-ERCP pancreatitis occurred in patients who received somatostatin prophylaxis. This finding suggests that the administration of somatostatin is useful in preventing pancreatitis in patients undergoing therapeutic ERCP. SN - 1536-4828 UR - https://www.unboundmedicine.com/medline/citation/18953260/The_prophylactic_effect_of_somatostatin_on_post_therapeutic_endoscopic_retrograde_cholangiopancreatography_pancreatitis:_a_randomized_multicenter_controlled_trial_ L2 - https://doi.org/10.1097/MPA.0b013e3181733721 DB - PRIME DP - Unbound Medicine ER -